Phytochemical Modulation of NF-κB Signaling in Pancreatic Ductal Adenocarcinoma: Preclinical Progress and Pharmacological Perspectives

Pancreatic ductal adenocarcinoma (PDAC) remains characterized by aggressive progression, extensive stromal remodeling, early metastatic dissemination, and resistance to systemic therapy. Nuclear factor kappa B (NF-κB) integrates oncogenic, inflammatory, survival, angiogenic, and treatment-induced signals and therefore represents a pharmacologically relevant regulatory node in pancreatic cancer. Phytochemicals including curcumin, xanthohumol, parthenolide, dimethylaminoparthenolide, triptolide, resveratrol, emodin, and related compounds have been investigated as modulators of NF-κB activity, although the strength of mechanistic evidence differs substantially among agents. This review evaluates canonical and noncanonical NF-κB biology in pancreatic cancer, interactions with KRAS, PI3K-AKT, STAT3, MAPK, and Nrf2 signaling, and the consequences of NF-κB modulation for apoptosis, epithelial–mesenchymal transition, angiogenesis, tumor microenvironmental communication, and chemotherapy resistance. Particular emphasis is placed on separating direct pharmacodynamic evidence from downstream pathway association and computational prediction. Curcumin and xanthohumol have been evaluated using direct NF-κB measurements linked to defined antitumor phenotypes and in vivo validation, whereas parthenolide and dimethylaminoparthenolide support a mechanistic relationship between NF-κB activity and gemcitabine resistance. Clinical evidence remains limited and is dominated by early phase curcumin studies, which also illustrate major barriers involving bioavailability, tumor exposure, and target engagement. Future development requires exposure–response analysis, cell-type-specific pharmacodynamics, rational combination therapy, validated biomarkers, and formulations or derivatives with improved pharmacokinetic properties. An evidence-based pharmacological framework may clarify which phytochemical NF-κB modulators warrant further translational development and biomarker-guided evaluation in PDAC.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-11-17
DOI
https://doi.org/10.3390/ph19111828
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Phytochemical Modulation of NF-κB Signaling in Pancreatic Ductal Adenocarcinoma: Preclinical Progress and Pharmacological Perspectives

Samra Siddiqui, Amit Baran Sharangi, Khurshid Ahmad, Mοhd Saeed et al.
Pharmaceuticals
Pancreatic and Hepatic Oncology Research
article

Phytochemical Modulation of NF-κB Signaling in Pancreatic Ductal Adenocarcinoma: Preclinical Progress and Pharmacological Perspectives

Samra Siddiqui, Amit Baran Sharangi, Khurshid Ahmad, Mοhd Saeed, Moniba Rahim, Suddhasuchi Das, Syed M. Faisal, Nida Khan
article en

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains characterized by aggressive progression, extensive stromal remodeling, early metastatic dissemination, and resistance to systemic therapy. Nuclear factor kappa B (NF-κB) integrates oncogenic, inflammatory, survival, angiogenic, and treatment-induced signals and therefore represents a pharmacologically relevant regulatory node in pancreatic cancer. Phytochemicals including curcumin, xanthohumol, parthenolide, dimethylaminoparthenolide, triptolide, resveratrol, emodin, and related compounds have been investigated as modulators of NF-κB activity, although the strength of mechanistic evidence differs substantially among agents. This review evaluates canonical and noncanonical NF-κB biology in pancreatic cancer, interactions with KRAS, PI3K-AKT, STAT3, MAPK, and Nrf2 signaling, and the consequences of NF-κB modulation for apoptosis, epithelial–mesenchymal transition, angiogenesis, tumor microenvironmental communication, and chemotherapy resistance. Particular emphasis is placed on separating direct pharmacodynamic evidence from downstream pathway association and computational prediction. Curcumin and xanthohumol have been evaluated using direct NF-κB measurements linked to defined antitumor phenotypes and in vivo validation, whereas parthenolide and dimethylaminoparthenolide support a mechanistic relationship between NF-κB activity and gemcitabine resistance. Clinical evidence remains limited and is dominated by early phase curcumin studies, which also illustrate major barriers involving bioavailability, tumor exposure, and target engagement. Future development requires exposure–response analysis, cell-type-specific pharmacodynamics, rational combination therapy, validated biomarkers, and formulations or derivatives with improved pharmacokinetic properties. An evidence-based pharmacological framework may clarify which phytochemical NF-κB modulators warrant further translational development and biomarker-guided evaluation in PDAC.

PharmaceuticalsVol. 19(11)
Bidhan Chandra Krishi Viswavidyalaya (IN), Qassim University (SA), Integral University (IN), King Faisal Specialist Hospital & Research Centre (SA), University of Ha'il (SA)
Good health and well-being
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon